Lv5
1115 积分 2022-03-31 加入
Reprogramming the tumor immune microenvironment via antibody-drug conjugates
1天前
已完结
Abstract 5567:In vivoadministration of the STING agonist, JNJ-67544412, leads to complete regression of established murine subcutaneous tumors
20天前
已关闭
Structure-guided computational design of novel polycyclic aromatic compounds as telomerase inhibitors for the treatment of cancer
1个月前
已完结
SIM0708, an antibody-drug conjugate (ADC) with half-life extended anti-IL-4 receptor a (IL-4Ra) antibody and glucocorticoid receptor modulator exhibits superior efficacy treating inflammatory diseases 4657
3个月前
已关闭
An In Vitro Model of Hematotoxicity: Differentiation of Bone Marrow–Derived Stem/Progenitor Cells into Hematopoietic Lineages and Evaluation of Lineage‐Specific Hematotoxicity
3个月前
已完结
An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability
3个月前
已完结
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors
3个月前
已完结
Trastuzumab deruxtecan efficacy, FcRn-facilitated penetration of the blood-tumor barrier, and distribution to tumor cells in HER2+ brain metastasis model systems
3个月前
已完结
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
4个月前
已完结
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
4个月前
已完结
皖公网安备34019202002308
